Long-term response to regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A systematic literature review (SLR)

被引：0
|
作者：
Peeters, M. [1 ]
Pan, X. [2 ]
Koufopoulou, M. [3 ]
Arregui, M. [4 ]
Wissinger, E. [5 ]
Ostojic, H. [6 ]
Pisa, F. [7 ]
Kim, R. D. [8 ]
机构：
[1] Univ Hosp Antwerp, Ctr Oncol Res, Edegem, Belgium
[2] Bayer Healthcare Pharmaceut Inc, Real World Evidence Oncol, Whippany, NJ 07981 USA
[3] Cencora, Evidence Generat & Value Commun, London, England
[4] Cencora, Evidence Generat & Value Commun, Hannover, Germany
[5] Cencora, Evidence Generat & Value Commun, Conshohocken, PA USA
[6] Bayer Consumer Care AG, Global Med Affairs, Basel, Switzerland
[7] Bayer AG, Real World Evidence Oncol, Berlin, Germany
[8] H Lee Moffitt Canc Ctr & Res Inst, Gastrointestinal Oncol, Tampa, FL USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.075
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64P
引用
收藏
页码：S30 / S31
页数：2
相关论文
共 50 条
  • [31] Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.
    Ducreux, Michel
    Ohler, Leopold
    Scheithauer, Werner
    Metges, Jean-Philippe
    Dourthe, Louis-Marie
    De Groot, Jan Willem
    Thaler, Josef
    Yeh, Kun-Huei
    Lin, Jen-Kou
    Falcone, Alfredo
    Punt, Cornelis J. A.
    Kalinovsky, Jan
    Fiala-Buskies, Sabine
    Cervantes, Andres
    O'Connor, Juan Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial
    Koechert, K.
    Beckmann, G.
    Teufel, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Factors associated with effectiveness of trifluridine/tipiracil versus regorafenib in patients with pretreated metastatic colorectal cancer (mCRC)
    Grell, Peter
    Borilova, Simona
    Schwanzerova, Renata
    Kukolikova, Sabina
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Buchler, Tomas
    Selingerova, Iveta
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Kiss, Igor
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer (mCRC) patients: a systematic literature review and meta-analysis
    Bylsma, Lauren C.
    Levin-Sparenberg, Elizabeth D.
    Lowe, Kimberly
    Sangare, Laura
    Fryzek, Jon
    Alexander, Dominik D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 440 - 440
  • [35] Comparison of the real-world adherence and compliance patterns with trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
    Patel, Anuj K.
    Duh, Mei Sheng
    Barghout, Victoria
    Yenikomshian, Mihran Ara
    Xiao, Yongling
    Wynant, Willy
    Tabesh, Majid
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] Long-term survivors (LTSs) population of metastatic colorectal cancer (mCRC): A Northern Italian comprehensive cancer center experience
    Damato, Angela
    Rotolo, Martina
    Borghi, Eleonora
    Caputo, Francesco
    Iachetta, Francesco
    Panebianco, Michele
    Fanello, Silvia
    Lombardi, Mattia
    Gervasi, Erika
    Larocca, Mario
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progressionfree survival (PFS) longer than 4 months
    Stein, A.
    Grothey, A.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Humblet, Y.
    Bouche, O.
    Mineur, L.
    Barone, C.
    Adenis, A.
    Tabemero, J.
    Yoshino, T.
    Lenz, H. -J
    Goldberg, R. M.
    Xu, L.
    Wagner, A.
    van Cutsem, E.
    Oncology Research and Treatment, 2015, 38 : 61 - 61
  • [38] Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study.
    Ducreu, Michel
    Ohler, Leopold
    Scheithauer, Werner
    Metges, Jean-Philippe
    Dourthe, Louis-Marie
    De Groot, Jan Willem
    Thaler, Joseph
    Yeh, Kun-Huei
    Lin, Jen-Kou
    Falcone, Alfredo
    Punt, Cornelis J. A.
    Contijoch, Ann M.
    Fiala-Buskies, Sabine
    Cervantes-Ruiperez, Andres
    Connor, Juan Manuel O.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [39] Long-Term Risk of Colorectal Cancer in Patients With Prediabetes : A Systematic Review and Meta-Analysis
    Keesari, Praneeth Reddy
    Pulakurthi, Yashwitha Sai
    Pannala, Sreeram
    Valluri, Jnana Pramod
    Mopuru, Nikhilendhar Nag
    Pingili, Adhvithi
    Ginjupalli, Manasa
    Jitta, Sahas Reddy
    Vattikuti, Rishi Devaraja
    Asfeen, Ummul
    Desai, Rupak
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S103 - S103
  • [40] Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC).
    Komatsu, Yoshito
    Muro, Kei
    Yamaguchi, Kensei
    Satoh, Taroh
    Uetake, Hiroyuki
    Yoshino, Takayuki
    Nishida, Toshirou
    Takikawa, Hajime
    Kato, Takeyuki
    Chosa, Masayuki
    Sunaya, Toshiyuki
    Yamamoto, Yuka
    Hamada, Yoko
    Watanabe, Toshiaki
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345